What is SR9009?
SR9009, commonly known as Stenabolic, is a synthetic Rev-Erb agonist designed to mimic many of the metabolic adaptations that physical exercise produces, without requiring the exercise itself. It works by binding to Rev-Erb alpha and beta receptors, nuclear proteins that play a central role in regulating circadian rhythm, mitochondrial biogenesis, lipid metabolism, and glucose homeostasis. The result is a compound that meaningfully increases energy expenditure, enhances fat utilization, and produces a clean and natural feeling of wakefulness and energy that makes it highly practical as a morning compound or pre-cardio tool. As an injectable, its bioavailability is substantially higher than oral formats, which historically suffered from poor absorption.
Mechanisms of Action
Rev-Erb receptor agonism activating Rev-Erb alpha and beta nuclear receptors that regulate core circadian and metabolic gene expression programs, influencing how and when the body burns energy
Enhanced glucose and fatty acid oxidation by upregulating metabolic gene expression that promotes the breakdown of both glucose and stored fat for energy, increasing overall energy expenditure
Mitochondrial biogenesis stimulation driving the production of new mitochondria in muscle and other metabolically active tissues, improving cellular energy output and aerobic capacity
Circadian rhythm modulation through Rev-Erb activity in the suprachiasmatic nucleus and peripheral tissues, influencing the sleep-wake cycle and contributing to its nootropic and wakefulness-promoting effects
Lipid metabolism optimization reducing lipid storage and promoting fat clearance through Rev-Erb-mediated regulation of lipogenic gene expression in adipose and hepatic tissue
Benefits
Increased endurance and stamina through enhanced mitochondrial function and improved utilization of both glucose and fatty acids as fuel, making sustained aerobic output feel significantly easier
Clean, natural energy upon waking with users describing the wakefulness effect as feeling like they had a perfect night of sleep regardless of actual sleep quality, making it an exceptional morning compound
Accelerated fat loss via increased metabolic rate and preferential fat oxidation, particularly effective when paired with fasted cardio immediately after morning dosing
Enhanced mitochondrial function contributing to improved overall vitality, cellular energy production, and aerobic performance capacity
Nootropic effects driven by its role in circadian rhythm regulation, producing improved focus and mental energy particularly in the early part of the day
Cardiac health support with preclinical research suggesting beneficial effects on cardiac function and metabolic markers relevant to cardiovascular health
Potential anti-cancer properties observed in early rat and in-vitro studies, with Rev-Erb activation showing promising effects in certain cancer models, though human data is still limited
Dosing
Use Case | Dose | Timing |
|---|---|---|
Morning wake-up and fasted cardio | 30 mg (1 ml) | Upon waking |
Post-nap energy boost | 10 mg | After mid-day nap |
Taking 30 mg upon waking provides a strong and clean energy effect that carries well into fasted cardio immediately afterward. A smaller 10 mg dose post-nap can help restore alertness naturally without the overstimulation of caffeine-based compounds. Due to SR9009's short half-life, splitting doses across the day is a practical approach for sustained metabolic and energy effects.
Note: SR9009's influence on circadian rhythm means timing of doses matters. Avoid dosing too late in the day as it may interfere with sleep onset. Human research on SR9009 remains limited and most data comes from preclinical models, so a cautious and informed approach to dosing is appropriate.
Safety Profile
Potential sleep pattern disruption given its role in circadian rhythm regulation, late-day dosing may interfere with the ability to fall asleep; morning and early afternoon dosing is preferred
Limited human safety data with most research conducted in animal models, meaning the full side effect profile in humans is not yet well-established and a conservative approach to dosing is warranted
Citations
PubChem Compound Summary for SR9009 (CID: 53394008). National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/53394008
Solt, L. A., et al. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. PubMed. https://pubmed.ncbi.nlm.nih.gov/22460951/
Disclaimer: The information provided is intended solely for educational purposes and should not be considered a replacement for professional medical advice. All compounds referenced are not for human consumption.
